At the height of the pandemic, Chinese vaccine maker Sinovac was a hero and one of the country’s most promising companies. But its success masked a protracted dispute between rival investors and management for control of the cash-rich company. The Wire China investigates what went wrong.
People receive COVID-19 vaccines at a vaccination site in a stadium in Minhang District, Shanghai, March 28, 2021. Credit: Liu Ying/Xinhua via Getty Images
It was past dusk when Sinovac’s special shareholders meeting kicked off in St. John’s, Antigua on July 8. At a law firm tucked into a back alley, a short drive away from the country's High Court building, a throng of lawyers prepared to square off in the latest round of a years-long fight for control of China’s flagship COVID-19 vaccine maker.
Several tumultuous weeks of legal proceedings had built to this point. The two factions competing for control of Nasdaq-listed Sinovac had be
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Fish farming in Xinjiang is being sold as proof that technology can overcome geography. The reality is more complicated: a desert seafood boom built on political control, imported feed and a food system that masks its real burdens.
The foreign correspondent describes meeting with the Uyghurs from Xinjiang who played a key role in the Syrian civil war, but who now find themselves potentially stateless.
Corporate Risk Intelligence for National Security, Compliance & Due Diligence
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
